Who founded Onconova Therapeutics?

Onconova Therapeutics was founded by Ramesh Kumar, Ph.D, E. Premkumar Reddy in 1998.

Who are Onconova Therapeutics's investors?

Onconova Therapeutics's investors include OrbiMed.

How much funding has Onconova Therapeutics raised?

Onconova Therapeutics has disclosed $17.3M raised across 4 of its 5 known rounds.

Where is Onconova Therapeutics headquartered?

Onconova Therapeutics is headquartered in Newtown, US.

Onconova Therapeutics

NASDAQ: TRAW

Newtown, US · Founded 1998 · Delaware corporation · 19 employees on LinkedIn · 1 known investors

Find your way into Onconova Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Onconova Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Traws Pharma (formerly Onconova Therapeutics) develops investigational antiviral agents targeting respiratory viral infections and certain cancers, with four clinical-stage programs including a cap-dependent endonuclease inhibitor for influenza and bird flu, a protease inhibitor for COVID-19, and two kinase inhibitors for solid tumors and blood cancers.

Biotech

Founders & leadership

Onconova Therapeutics was founded in 1998 by Ramesh Kumar, Ph.D and E. Premkumar Reddy.

Ramesh Kumar, Ph.DCo-founder

E. Premkumar ReddyCo-founder

Manoj ManiarExecutive

Thomas McKearnExecutive

Ajay Bansal CFO2013–2016Ajay Bansal served as CFO at multiple biotech and pharmaceutical companies including Nektar Therapeutics, Lexicon Pharmaceuticals, Complete Genomics, Onconova Therapeutics, and Urovant Sciences, leading IPOs and M&A transactions totaling over $1 billion in capital raised. His background includes roles at Novartis, McKinsey, ZS Associates, and Mehta Partners spanning finance, strategy, business development, and commercial functions.

Steven Fruchtman President and CEO2019–2024Steven Fruchtman is President and CEO of Onconova Therapeutics (now Traws Pharma), where he has served for over a decade, and holds a medical background that has informed his leadership of clinical development programs in hematology and oncology.

Iain Dukes Chief Executive Officer, Secretary and DirectorIain Dukes holds a doctorate in physiology and pharmacology from Oxford University and has held senior roles in pharmaceutical business development and licensing at Merck, Amgen, and GlaxoSmithKline, as well as serving as President and CEO of Essentialis Therapeutics before joining Orbimed as a Venture Partner.

Charles ParkerChief Financial Officer

Nikolay SavchukChief Operating Officer and Director

C. David PauzaChief Science Officer, Virology

Robert R. RedfieldChief Medical Officer

Victor Moyo Chief Medical OfficerVictor Moyo serves as Chief Medical Officer at Onconova Therapeutics (now Traws Pharma). He has over two decades of pharmaceutical experience, including prior roles as Chief Medical Officer at OncoPep, Inc. and Executive Vice President and Chief Medical Officer at L.E.A.F. Pharmaceuticals, with expertise in oncology drug development, regulatory submissions, and clinical advancement.

Investors · 1

OrbiMedreportedNew York · $1M – $75M

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$17.3M disclosed across 4 of 5 rounds · 2015–2024

▶$14MraisedApr 2024 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

M. Theresa ShoemakerDirector
Jack E. StoverDirector
Trafford ClarkeDirector
Nikolay SavchukDirector, Executive Officer
Ian DukesDirector
David PauzaExecutive Officer
Robert RedfieldExecutive Officer
Mark GuerinExecutive Officer
Steven FruchtmanExecutive Officer
Werner CautreelsDirector, Executive Officer
James MarinoDirector

Offering amount: $14M
Amount sold: $14M
Sales commissions: $1M
First sale: Apr 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$500KraisedJun 2019 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Michael B. HoffmanDirector
Jerome E. GroopmanDirector
Abraham N. OlerExecutive Officer
Viren MehtaDirector
James J. MarinoDirector
Premkumar ReddyDirector
Jack E. StoverDirector
Steven M. FruchtmanExecutive Officer, Director
Manoj ManiarExecutive Officer
Mark P. GuerinExecutive Officer
Richard C. WoodmanExecutive Officer

Offering amount: $2M
Amount sold: $500K
Minimum investment: $500K
First sale: May 2019
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.3MraisedJun 2018 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Michael B. HoffmanDirector
Jerome E. GroopmanDirector
Mark P. GuerinExecutive Officer
Jack E. StoverDirector
Ramesh KumarExecutive Officer, Director
Manoj ManiarExecutive Officer
E. Premkumar ReddyDirector
Steven M. FruchtmanExecutive Officer
Henry S. BienenDirector
James J. MarinoDirector
Viren MehtaDirector

Offering amount: $1.3M
Amount sold: $1.3M
Minimum investment: $1.3M
Sales commissions: $75K
Placement agents: Lucas Advisors LLC d/b/a KYBORA Emerging Markets
First sale: Apr 2018
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.5MraisedOct 2015 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Manoj ManiarExecutive Officer
Thomas McKearnExecutive Officer
Ajay BansalExecutive Officer
Anne M. VanLentDirector
Henry S BienenDirector
Ramesh Kumar, Ph.DExecutive Officer, Director
E. Premkumar ReddyDirector
James MarinoDirector
Jerome E. GroopmanDirector
Michael HoffmanDirector
Viren MehtaDirector
Steven FruchtmanExecutive Officer

Offering amount: $16.5M
Amount sold: $1.5M
Minimum investment: $1.5M
Proceeds to insiders: $100K
First sale: Oct 2015
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Onconova Therapeutics do?: Traws Pharma (formerly Onconova Therapeutics) develops investigational antiviral agents targeting respiratory viral infections and certain cancers, with four clinical-stage programs including a cap-dependent endonuclease inhibitor for influenza and bird flu, a protease inhibitor for COVID-19, and two kinase inhibitors for solid tumors and blood cancers.
Who founded Onconova Therapeutics?: Onconova Therapeutics was founded by Ramesh Kumar, Ph.D, E. Premkumar Reddy in 1998.
Who are Onconova Therapeutics's investors?: Onconova Therapeutics's investors include OrbiMed.
How much funding has Onconova Therapeutics raised?: Onconova Therapeutics has disclosed $17.3M raised across 4 of its 5 known rounds.
Where is Onconova Therapeutics headquartered?: Onconova Therapeutics is headquartered in Newtown, US.